{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:05:32Z","timestamp":1790355932481,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.phrs.2017.05.022","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T02:31:26Z","timestamp":1496111486000},"page":"53-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials"],"prefix":"10.1016","volume":"122","author":[{"given":"Amirhossein","family":"Sahebkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Simental-Mend\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri T.","family":"Kovanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Simental-Mend\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bianconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.05.022_bib0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.05.022_bib0010","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000343803","article-title":"Obesity and the cardiorenal metabolic syndrome: therapeutic modalities and their efficacy in improving cardiovascular and renal risk factors","volume":"2","author":"Jindal","year":"2012","journal-title":"Cardiorenal Med."},{"key":"10.1016\/j.phrs.2017.05.022_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2017.05.022_bib0020","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2017.05.022_bib0025","unstructured":"Anon. Xenical (orlistat) prescribing information. http:\/\/www.gene.com\/download\/pdf\/xenical_prescribing.pdf. Accessed 22, February, 2015."},{"key":"10.1016\/j.phrs.2017.05.022_bib0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.05.022_bib0035","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2017.05.022_bib0040","first-page":"5A","article-title":"Cholesterol and lipids in the risk of coronary artery disease \u2212 the Framingham Heart Study","volume":"4","author":"Castelli","year":"1988","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0045","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.05.022_bib0050","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European association for cardiovascular prevention & rehabilitation (EACPR), ESC committee for practice guidelines (CPG): European guidelines on cardiovascular disease prevention in clinical practice (version 2012)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2017.05.022_bib0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000381304","article-title":"Are elevated serum triglycerides really a risk factor for Coronary artery disease","volume":"131","author":"Reiner","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.phrs.2017.05.022_bib0060","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2017.05.022_bib0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejim.2011.04.007","article-title":"Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic","volume":"22","author":"Pirro","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.phrs.2017.05.022_bib0070","unstructured":"K.R. Feingold, C. Grunfeld. Obesity and Dyslipidemia. (eds De Groot LJ et al.) (South Dartmouth 2000\u20132015)."},{"key":"10.1016\/j.phrs.2017.05.022_bib0075","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. A position paper by the Residual Risk Reduction Initiative (R3I)","volume":"4","author":"Fruchart","year":"2008","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.phrs.2017.05.022_bib0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14656566.2014.876992","article-title":"New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease","volume":"15","author":"Sahebkar","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2017.05.022_bib0085","doi-asserted-by":"crossref","first-page":"e39062","DOI":"10.1371\/journal.pone.0039062","article-title":"Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2017.05.022_bib0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.numecd.2006.03.004","article-title":"Orlistat increases serum paraoxonase activity in obese patients","volume":"17","author":"Audikovszky","year":"2007","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.phrs.2017.05.022_bib0095","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/00004872-200211000-00026","article-title":"orlistat and resistant hypertension investigators:Orlistat and resistant hypertension investigators. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension","volume":"20","author":"Bakris","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.05.022_bib0100","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2337\/diacare.26.6.1667","article-title":"Yki-J\u00e4rvinen H. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes","volume":"26","author":"Bergholm","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2017.05.022_bib0105","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1097\/00004872-200311000-00026","article-title":"Orlistat in hypertensive overweight\/obese patients: results of a randomized clinical trial","volume":"21","author":"Bloch","year":"2003","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.05.022_bib0110","first-page":"538","article-title":"Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients","volume":"30","author":"Chou","year":"2007","journal-title":"Chang Gung Med. J."},{"key":"10.1016\/j.phrs.2017.05.022_bib0115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1527-5299.2005.03827.x","article-title":"Effect of Orlistat in obese patients with heart failure: a pilot study","volume":"11","author":"Beck-da-Silva","year":"2005","journal-title":"Congest. Heart Fail."},{"key":"10.1016\/j.phrs.2017.05.022_bib0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2017.05.022_bib0125","first-page":"1361","article-title":"A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia","volume":"28","author":"de Castro","year":"2009","journal-title":"Rev. Port. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1463-1326.2004.00372.x","article-title":"Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients","volume":"7","author":"Derosa","year":"2005","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2017.05.022_bib0135","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0149-2918(03)80070-X","article-title":"Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet","volume":"25","author":"Derosa","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2017.05.022_bib0140","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1365-2036.2004.01966.x","article-title":"Cholesterol lowering effect of dietary weight loss and orlistat treatment\u2013efficacy and limitations","volume":"19","author":"Erdmann","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2017.05.022_bib0145","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1463-1326.2007.00733.x","article-title":"The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome","volume":"10","author":"Filippatos","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2017.05.022_bib0150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.phrs.2017.05.022_bib0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1462-8902.2004.00359.x","article-title":"Effects of orlistat on obesity-related diseases \u2013 a six-month randomized trial","volume":"6","author":"Guy-Grand","year":"2004","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2017.05.022_bib0160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1463-1326.2003.00262.x","article-title":"Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients","volume":"5","author":"Halpern","year":"2003","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2017.05.022_bib0165","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study","volume":"69","author":"Hill","year":"1999","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.phrs.2017.05.022_bib0170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diabres.2004.05.012","article-title":"Orlistat for obesity: benefits beyond weight loss","volume":"67","author":"Hsieh","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2017.05.022_bib0175","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1210\/jc.2004-0176","article-title":"Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome","volume":"90","author":"Jayagopal","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2017.05.022_bib0180","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2017.05.022_bib0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study","volume":"248","author":"Lindg\u00e4rde","year":"2000","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2017.05.022_bib0190","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0002-9149(03)00112-7","article-title":"Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia","volume":"91","author":"Lucas","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0195","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2017.05.022_bib0200","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.ijo.0801814","article-title":"The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"25","author":"Muls","year":"2001","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.phrs.2017.05.022_bib0205","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1517\/14656560802548430","article-title":"The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia","volume":"9","author":"Nakou","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2017.05.022_bib0210","first-page":"1","article-title":"Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience","volume":"30","author":"Pathan","year":"2004","journal-title":"Bangladesh Med. Res. Counc. Bull."},{"key":"10.1016\/j.phrs.2017.05.022_bib0215","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.ijo.0802439","article-title":"Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification","volume":"27","author":"Poston","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.phrs.2017.05.022_bib0220","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0002-9149(00)01521-6","article-title":"Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X","volume":"87","author":"Reaven","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2337\/dc06-0210","article-title":"Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study","volume":"30","author":"Richelsen","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2017.05.022_bib0230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity:European Orlistat Obesity Study Group","volume":"8","author":"R\u00f6ssner","year":"2000","journal-title":"Obes. Res."},{"key":"10.1016\/j.phrs.2017.05.022_bib0235","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.05.022_bib0240","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1463-1326.2004.00467.x","article-title":"Effect of orlistat on cardiovascular disease risk in obese adults","volume":"7","author":"Swinburn","year":"2005","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2017.05.022_bib0245","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00191901","article-title":"The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia","volume":"46","author":"Tonstad","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/archinternmed.2009.492","article-title":"A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss","volume":"170","author":"Yancy","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2017.05.022_bib0255","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1586\/erc.11.83","article-title":"Treatment of lipid disorders in obesity","volume":"9","author":"Tonstad","year":"2011","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.phrs.2017.05.022_bib0260","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.phrs.2017.05.022_bib0265","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2017.05.022_bib0270","series-title":"Comprehensive Meta-analysis Version 2","first-page":"104","author":"Borenstein","year":"2005"},{"key":"10.1016\/j.phrs.2017.05.022_bib0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0280","series-title":"Methods for Meta-Analysis in Medical Research","author":"Sutton","year":"2000"},{"key":"10.1016\/j.phrs.2017.05.022_bib0285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.phrs.2016.04.021","article-title":"The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials","volume":"110","author":"Pirro","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.05.022_bib0290","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","article-title":"Analysis of vitamin D levels in patients with and without statin-associated myalgia \u2013 a systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Michalska-Kasiczak","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0295","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.phrs.2017.05.022_bib0300","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/sj.ijo.0803631","article-title":"Long-term persistence with orlistat and sibutramine in a population-based cohort","volume":"31","author":"Padwal","year":"2007","journal-title":"Int. J. Obes. (Lond.)"},{"key":"10.1016\/j.phrs.2017.05.022_bib0305","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.diabres.2011.08.021","article-title":"Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals","volume":"94","author":"Hemo","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2017.05.022_bib0310","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1467-789X.2009.00581.x","article-title":"Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis","volume":"10","author":"Johansson","year":"2009","journal-title":"Obes. Rev."},{"key":"10.1016\/j.phrs.2017.05.022_bib0315","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/oby.2001.79","article-title":"Orlistat inhibits dietary cholesterol absorption","volume":"9","author":"Mittendorfer","year":"2001","journal-title":"Obes. Res."},{"key":"10.1016\/j.phrs.2017.05.022_bib0320","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/clpt.1994.104","article-title":"Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers","volume":"56","author":"Zhi","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2017.05.022_bib0325","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/bj2560357","article-title":"Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin","volume":"256","author":"Hadv\u00e1ry","year":"1988","journal-title":"Biochem. J"},{"key":"10.1016\/j.phrs.2017.05.022_bib0330","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.phrs.2017.05.022_bib0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","article-title":"Recent advances in pharmacotherapy for hypertriglyceridemia","volume":"56","author":"Sahebkar","year":"2014","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.phrs.2017.05.022_bib0340","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jacl.2012.12.003","article-title":"A silent mutation of Niemann-Pick C1-like 1 and apolipoprotein E4 modulate cholesterol absorption in primary hyperlipidemias","volume":"7","author":"Lupattelli","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0345","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/01.ATV.18.3.441","article-title":"Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1","volume":"18","author":"Ginsberg","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2017.05.022_bib0350","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am. J. Med."},{"key":"10.1016\/j.phrs.2017.05.022_bib0355","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"23","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817304784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817304784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T03:00:41Z","timestamp":1569380441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817304784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":71,"alternative-id":["S1043661817304784"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.05.022","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}